Stock SLS SELLAS LIFE SCIENCES GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Real-time Estimate Cboe BZX
Other stock markets
 15:54:57 14/05/2024 BST 		5-day change 1st Jan Change
1.355 USD -1.09% Intraday chart for SELLAS Life Sciences Group, Inc. +1.14% +25.94%
05-01 SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level CI
04-29 SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SELLAS Life Sciences Group, Inc. Announces Executive Changes
CI
Athersys Names Jane Wasman as Board Chair
MT
SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer
CI
SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality
CI
SELLAS Life Sciences Group, Inc. Announces Election of Katherine Bach Kalin to Its Board of Directors
CI
SELLAS Life Sciences Appoints Robert Francomano as CCO
MT
SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer
CI
SELLAS Life Sciences Group, Inc. Promotes John T. Burns to Senior Vice President, Finance and Chief Accounting Officer
CI
Sellas Life Sciences Group, Inc. Announces Executive Changes
CI
SELLAS Life Sciences Group, Inc. Establishes Independent Data Monitoring Committee of Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial
CI
SELLAS Life Sciences Group, Inc. Names Dragan Cicic, MD, as Senior Vice President, Clinical Development
CI
SELLAS Life Sciences Group, Inc. Announces Executive Changes
CI
SELLAS Life Sciences Group, Inc. Announces Management Appointments
CI
SELLAS Life Sciences Group, Inc. Announces Resignation of Fabio López from the Board of Directors, Effective July 27, 2018
CI
SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients; Appoints Jeffrey S. Weber as Chairman
CI
SELLAS Life Sciences Group, Inc Appoints Gregory M. Torre as Chief Regulatory Officer and Senior Vice President, Technical Operations Effective April 27, 2018
CI
SELLAS Life Sciences Group, Inc. Announces Executive Changes
CI
SELLAS Life Sciences Group Inc. Appoints Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary
CI
SELLAS Life Sciences Appoints Jane Wasman as Chair of Board of Directors
CI
SELLAS Life Science Group, Inc. to Appoint Angelos M. Stergiou as Chief Executive Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLS Stock
  4. News SELLAS Life Sciences Group, Inc.
  5. Insiders